SG11202110889WA - Dosage forms and regimens for amino acid compounds - Google Patents
Dosage forms and regimens for amino acid compoundsInfo
- Publication number
- SG11202110889WA SG11202110889WA SG11202110889WA SG11202110889WA SG11202110889WA SG 11202110889W A SG11202110889W A SG 11202110889WA SG 11202110889W A SG11202110889W A SG 11202110889WA SG 11202110889W A SG11202110889W A SG 11202110889WA SG 11202110889W A SG11202110889W A SG 11202110889WA
- Authority
- SG
- Singapore
- Prior art keywords
- regimens
- amino acid
- dosage forms
- acid compounds
- compounds
- Prior art date
Links
- -1 amino acid compounds Chemical class 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962831060P | 2019-04-08 | 2019-04-08 | |
| US201962850530P | 2019-05-20 | 2019-05-20 | |
| US201962899071P | 2019-09-11 | 2019-09-11 | |
| PCT/US2020/027335 WO2020210404A1 (en) | 2019-04-08 | 2020-04-08 | Dosage forms and regimens for amino acid compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202110889WA true SG11202110889WA (en) | 2021-10-28 |
Family
ID=72750659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202110889WA SG11202110889WA (en) | 2019-04-08 | 2020-04-08 | Dosage forms and regimens for amino acid compounds |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11419869B2 (en) |
| EP (1) | EP3952902A4 (en) |
| JP (1) | JP2022526818A (en) |
| CN (1) | CN114173803A (en) |
| AU (1) | AU2020273158A1 (en) |
| CA (1) | CA3136745A1 (en) |
| IL (1) | IL287004A (en) |
| SG (1) | SG11202110889WA (en) |
| WO (1) | WO2020210404A1 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201823208A (en) | 2016-09-07 | 2018-07-01 | 美商普萊恩醫療公司 | N-acyl amino acid compounds and methods of use |
| WO2018119087A1 (en) | 2016-12-23 | 2018-06-28 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| TW201835078A (en) | 2017-02-28 | 2018-10-01 | 美商萊築理公司 | Inhibitors of [alpha]v[beta]6 integrin |
| CA3054792A1 (en) | 2017-02-28 | 2018-09-07 | Morphic Therapeutic, Inc. | Inhibitors of .alpha.v.beta.6 integrin |
| PL3761980T3 (en) | 2018-03-07 | 2024-06-10 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| MX2020014086A (en) | 2018-06-27 | 2021-04-13 | Pliant Therapeutics Inc | Amino acid compounds with unbranched linkers and methods of use. |
| BR112021003859A2 (en) | 2018-08-29 | 2021-05-18 | Morphic Therapeutic, Inc. | inhibiting avss6 integrin |
| TW202028179A (en) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | Amino acid compounds and methods of use |
| SG11202110889WA (en) | 2019-04-08 | 2021-10-28 | Pliant Therapeutics Inc | Dosage forms and regimens for amino acid compounds |
| KR20230121761A (en) * | 2020-11-19 | 2023-08-21 | 플라이언트 테라퓨틱스, 인크. | Integrin inhibitors and uses thereof |
| WO2022165000A1 (en) * | 2021-01-27 | 2022-08-04 | Shy Therapeutics, Llc | Methods for the treatment of fibrotic disease |
| WO2022164997A1 (en) * | 2021-01-27 | 2022-08-04 | Shy Therapeutics, Llc | Methods for the treatment of fibrotic disease |
| IL308063A (en) * | 2021-04-30 | 2023-12-01 | Pliant Therapeutics Inc | Expanded dosage regimens for integrin inhibitors |
| US20230293519A1 (en) * | 2021-10-14 | 2023-09-21 | Pliant Therapeutics, Inc. | Integrin inhibitors and uses thereof in combination with other agents |
| WO2023225119A1 (en) * | 2022-05-18 | 2023-11-23 | Pliant Therapeutics, Inc. | Stabilization of integrin inhibitors |
| WO2024015717A2 (en) * | 2022-07-09 | 2024-01-18 | Pliant Therapeutics, Inc. | Integrin inhibitors and uses thereof in combination with other agents |
| WO2024119067A1 (en) | 2022-12-02 | 2024-06-06 | Neumora Therapeutics, Inc. | Methods of treating neurological disorders |
| WO2024125634A1 (en) * | 2022-12-16 | 2024-06-20 | 西藏海思科制药有限公司 | Tetrahydronaphthyridine compound and application thereof in medicine |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE200000362A (en) | 1997-12-17 | 2001-12-17 | Merck & Co., Inc. | Integrin receptor antagonists, a pharmaceutical composition and a process for its preparation |
| US6048861A (en) | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| US7144897B2 (en) | 2001-06-01 | 2006-12-05 | Elan Oharmaceuticals, Inc. | Hydroxy alkyl amines |
| JP2005538177A (en) | 2002-09-10 | 2005-12-15 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | Substituted amino ether compounds for the treatment of Alzheimer's disease |
| ES2647585T3 (en) * | 2012-07-18 | 2017-12-22 | Saint Louis University | Beta amino acid derivatives as integrin antagonists |
| AU2014324426A1 (en) | 2013-09-30 | 2016-04-21 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| CA2981371A1 (en) | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| AU2017248750B2 (en) | 2016-04-14 | 2021-12-02 | Mars, Incorporated | Compounds that modulate calcium-sensing receptor activity for modulating kokumi taste and pet food products containing the same |
| CA3029829A1 (en) * | 2016-07-05 | 2018-01-11 | The Rockefeller University | Tetrahydronaphthyridinepentanamide integrin antagonists |
| TW201823208A (en) | 2016-09-07 | 2018-07-01 | 美商普萊恩醫療公司 | N-acyl amino acid compounds and methods of use |
| WO2018119087A1 (en) | 2016-12-23 | 2018-06-28 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| PL3761980T3 (en) * | 2018-03-07 | 2024-06-10 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| MX2020014086A (en) | 2018-06-27 | 2021-04-13 | Pliant Therapeutics Inc | Amino acid compounds with unbranched linkers and methods of use. |
| TW202028179A (en) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | Amino acid compounds and methods of use |
| SG11202110889WA (en) | 2019-04-08 | 2021-10-28 | Pliant Therapeutics Inc | Dosage forms and regimens for amino acid compounds |
| IL297969A (en) | 2020-05-07 | 2023-01-01 | Pliant Therapeutics Inc | Treatment of respiratory diseases with amino acid compounds |
-
2020
- 2020-04-08 SG SG11202110889WA patent/SG11202110889WA/en unknown
- 2020-04-08 JP JP2021559658A patent/JP2022526818A/en active Pending
- 2020-04-08 CN CN202080041929.2A patent/CN114173803A/en active Pending
- 2020-04-08 US US16/843,824 patent/US11419869B2/en active Active
- 2020-04-08 EP EP20786790.4A patent/EP3952902A4/en active Pending
- 2020-04-08 WO PCT/US2020/027335 patent/WO2020210404A1/en unknown
- 2020-04-08 AU AU2020273158A patent/AU2020273158A1/en active Pending
- 2020-04-08 CA CA3136745A patent/CA3136745A1/en active Pending
-
2021
- 2021-10-05 IL IL287004A patent/IL287004A/en unknown
-
2022
- 2022-07-20 US US17/869,758 patent/US20230117605A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114173803A (en) | 2022-03-11 |
| US20230117605A1 (en) | 2023-04-20 |
| IL287004A (en) | 2021-12-01 |
| WO2020210404A1 (en) | 2020-10-15 |
| US11419869B2 (en) | 2022-08-23 |
| EP3952902A1 (en) | 2022-02-16 |
| AU2020273158A1 (en) | 2021-11-11 |
| CA3136745A1 (en) | 2020-10-15 |
| US20200352942A1 (en) | 2020-11-12 |
| JP2022526818A (en) | 2022-05-26 |
| EP3952902A4 (en) | 2022-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287004A (en) | Dosage forms and regimens for amino acid compounds | |
| GB2594345B (en) | Single dosage shampoo | |
| GB201911928D0 (en) | Pharmaceutical compounds | |
| HUE065887T2 (en) | Amino acid compounds and methods of use | |
| IL271222A (en) | Dosage regimens for anti-tim-3 antibodies and uses thereof | |
| IL291452A (en) | Dosage forms for tyk2 inhibitors | |
| IL283859A (en) | Extended low dose regimens for mdm2 inhibitors | |
| GB201911944D0 (en) | Pharmaceutical compounds | |
| SG11202110534QA (en) | Cd73 inhibitors | |
| GB201911517D0 (en) | Pharmaceutical composition | |
| IL285134A (en) | Therapeutic antibody formulation | |
| GB201914910D0 (en) | Pharmaceutical compounds | |
| IL281357B (en) | Cd73 inhibitors and pharmaceutical uses thereof | |
| IL290894A (en) | Pharmaceutical formulation | |
| GB202103724D0 (en) | Pharmaceuticals solution for oral dosage | |
| IL291570A (en) | Pharmaceutical compounds | |
| GB202204938D0 (en) | Compounds comprising curcmin and basic amino acids | |
| IL287443A (en) | Dosage regimens for and compositions including anti-rsv antibodies | |
| HK1244674A1 (en) | An oral pharmaceutical formulation comprising sustained-release granules containing tamsulosin hydrochloride | |
| EP4055061A4 (en) | Dosage regimen for anti-egfrviii agents | |
| SG11202110315SA (en) | Pharmaceutical composition | |
| GB201915273D0 (en) | Pharmaceutical compounds | |
| LT3908321T (en) | Pharmaceutical composition | |
| GB201906473D0 (en) | Pharmaceutical formulation | |
| IL308389A (en) | Dosage regimens for ecubectedin |